Changes in the metabolism of three model substrates catalysed by different P450 isozymes when administered as a cocktail to the carbon tetrachloride-intoxicated rat

References

• Barcetzi M. J., Aoyama T., Gonzalez F. J., Meyer U. A. Lidocaine metabolism in human liver microsomes by cytochrome P450 IIIA4. Clinical Pharmacology and Therapeutics 1989; 46: 521–527
   PubMedGoogle Scholar
• Bienvenu T., Pons G., Rey E., Thiroux G., Olive G. Effect of pregnandiol on caffeine metabolismin female rats. European Journal of Drug Metabolism and Pharmacokinetics 1993; 18: 181–185
   PubMedGoogle Scholar
• Blaschke T. F., Meffin P. J., Melmon K. L., Rowland M. Influence of acute viral hepatitis on phenytoin kinetics and protein binding. Clinical Pharmacology and Therapeutics 1975; 17: 685–691
   PubMed Web of Science ®Google Scholar
• Breimer D. D. Assesment of drug oxidation in man in vivo. Human Drug Metabolism, E. H. Jeffery. CRC Press, London 1993; 35–42
   Google Scholar
• Brosen K. Recent developments in hepatic drug oxidation: implication for clinical pharmacokinetics. Clinical Pharmacokinetics 1990; 18: 220–239
   PubMed Web of Science ®Google Scholar
• Buters J. T. B., Zysset T., Reichen J. Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Biochemical Pharmacology 1991; 46: 983–991
   Google Scholar
• Butler M. A., Iwasaki M., Guengerich F. P., Kadlubar F. F. Human cytochrome P-450 pa (P-450 1A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethyiation of caffeine and N-oxidation of carcinogenic arylamines. Proceedings of the National Academy of Sciences of the United States of America 1989; 86: 7696–7700
   PubMed Web of Science ®Google Scholar
• Dickinson R. G., Hooper W. D., Patterson M., Eadie M. J., Maguire B. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Therapeutic Drug Montoring 1985; 7: 283–289
   PubMed Web of Science ®Google Scholar
• Glazko A. J., Peterson F. E., Chang T., Dil W. A., Smith T. C., Buchanan R. A. Phenytoin metabolism in subjects with long and short plasma half-lives. Therapeutic Drug Monitoring 1982; 4: 281–292
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J., Idle J. R. Pharmacogentic phenotyping and genotyping: present status and future potential. Clinical Pharmacokinetics 1994; 26: 59–70
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicology Letters 1994; 70: 133–138
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Turvy C. G. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. Journal of Pharmacology and Experimental Therapeutics 1991; 256: 1189–1993
   PubMed Web of Science ®Google Scholar
• Kolars J. C., Murray S. A., Peters K. M., Watkins P. B. Differential regulation of liver P-450III cytochromes in choline-deficient rats: implications for the eryhromycin breath test as a parameter of liver function. Hepatology 1990; 12: 1371–1378
   PubMedGoogle Scholar
• Lown K., Kolars, Turgeon K., Merion R., Wrighton S. A., Watkins P. B. The erythromycin breath test selectively measures P450 IIIA in patients with severe liver disease. Clinical Pharmacology and Therapeutics 1992; 51: 229–238
   PubMed Web of Science ®Google Scholar
• McLean A. J., Morgan D. J. Clinical pharmacokinetics in patients with liver disease. Clinical Pharmacokinetics 1991; 21: 42–69
   PubMed Web of Science ®Google Scholar
• Nakamura M., Tanaka E., Misawa S., Shimada T., Imaoka S., Funae Y. Trimethadione metabolism a useful indicator for assessing hepatic drug-oxidizing capacity. Biochemical Pharmacology 1994; 47: 247–251
   PubMed Web of Science ®Google Scholar
• Oellerich M., Burdelkski M., Ringe B., Lamesch P., Gubernatis G., Bunzendahl H., Pichimayr R., Herrmann H. Lighocaine metabolite formation as a measure of pre-transplant liver function. Lancet 1989; i: 640–642
   Google Scholar
• Pelkonen O., Breimer D. D. Role of environmental factors in the pharmacokinetics of drugs: considerations with respect to animal models, P-450 enzymes, and probe drugs. Handbook of Experimental Pharmacology, P. G. Welling, L. P. Balant. Springer, Berlin 1994; 289–332
   Google Scholar
• Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Soucek P., Gut I. Cytochrome P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 1992; 22: 83–103
   PubMed Web of Science ®Google Scholar
• Tanaka E. Simultaneous determination of caffeine and its primary demethylated metabolites in human plasma by high-performance liquid chromatography. Journal of Chromatography Biomedical Applications 1992; 575: 311–314
   PubMed Web of Science ®Google Scholar
• Tanaka E. Changes in caffeine, lidocaine and trimethadione metabolism in carbon tetrachloride-intoxicated rats as assessed by a ‘Cocktail’ study. Pharmacology and Toxicology 1994a; 75: 150–153
   PubMedGoogle Scholar
• Tanaka E., Etoh H., Ishikawa A., Nakano M., Misawa S. Influence of liver damage on antipyrine metabolite formation in rats. Xenobiotica 1991; 22: 535–541
   Google Scholar
• Tanaka E., Ishikawa A., Ono A., Okamura T., Kobayashi S., Yasuhara H., Misawa S. Trimethadione tolerance test for evaluation of functional reserved of the liver in patients with liver cirrhosis and esophageal varices. Journal of Pharmacobio-Dynamics 1986a; 9: 297–302
   PubMedGoogle Scholar
• Tanaka E., Ishihkawa A., Ono A., Takada A., Okamura T., Misawa S. Hepatic trimethadione-oxidizing capacity remains normal in patients with extrahepatic cholelithiasis. Journal of Pharmacobio-Dynamics 1986b; 9: 506–509
   PubMedGoogle Scholar
• Tanaka E., Kinoshits H., Yoshida T., Kuroiwa Y. Determination of plasma trimethadione and its metabolite in carbon tetrachloride intoxicated rat liver: a useful tool for estimation of hepatic drug-metabolizing capacity. Journal of Pharmacobio-Dynamics 1981; 4: 961–967
   PubMedGoogle Scholar
• Tanaka E., Kinoshita H., Yoshida T., Kuroiwa Y. Trimethadione as a model drug for the evaluation of hepatic drug-metabolizing capacity in normal and α-naphthylisothiocyanate intoxicated rats. Pharmacology 1982a; 25: 202–209
   PubMedGoogle Scholar
• Tanaka E., Kinoshita H., Yoshida T., Kuroiwa Y. Trimethadione as a model drug for the evaluation of hepatic drug-metabolizing capacity in normal and D-galactosamine intoxicated rats. Japanese Journal of Pharmacology 1982b; 32: 1182–1185
   PubMedGoogle Scholar
• Tanaka E., Yamamoto Y., Ishikawa A., Osada A., Tsuji K., Fukao K. Effect of cigarette smoking on caffeine and trimethadione N-demethylation catalyzed by different cytochrome P450 isozymes in patients with cirrhosis. International Hepatology Communications 1994b; 2: 341–346
   Google Scholar
• Veronese M. E., Doecke C. J., Mackenzie P. I., McManus M. E., Miners J. O., Rees D. L. P., Gasser R., Meyer U. A., Birkett D. J. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochemical Journal 1993; 289: 533–538
   PubMed Web of Science ®Google Scholar
• Veronese M. E., Mackenzie P. I., Doecke C. J., MacManus M. E., Miners J. O., Birkett D. J. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytchrome P4502C9. Biochemical and Biophysical Research Communications 1991; 175: 1112–1118
   PubMed Web of Science ®Google Scholar